Key result
Adjusted-dose warfarin reduced cardioembolic strokes by 83% (p < 0.001) relative to aspirin in patients with atrial fibrillation.
Why the study?
Do antithrombotic therapies (adjusted-dose warfarin or aspirin) differentially reduce cardioembolic versus noncardioembolic strokes in patients with atrial fibrillation?
Population
3,950 participants with atrial fibrillation from the Stroke Prevention in Atrial Fibrillation I–III clinical…
Comparison
Adjusted-dose warfarin or aspirin vs Placebo or no antithrombotic therapy
Design
Cohort, Outcome assessors (neurologists) blinded to antithrombotic therapy
Authors
Loading...
Supports mechanism-specific antithrombotic effects in AF; leaves open targeted strategies for noncardioembolic events.
RCT (n=3,950)
Single-blind
Do antithrombotic therapies (adjusted-dose warfarin or aspirin) differentially reduce cardioembolic versus noncardioembolic strokes in patients with atrial fibrillation?
Effect estimate: 83% reduction
p-value: p=< 0.001
In patients with atrial fibrillation, adjusted-dose warfarin primarily prevents cardioembolic strokes, whereas aspirin appears to reduce noncardioembolic strokes.
Hart et al. (2000) conducted an RCT in Atrial fibrillation (n=3,950). Adjusted-dose warfarin vs. Aspirin, placebo, or no antithrombotic therapy was evaluated on Cardioembolic strokes (83% reduction, p=< 0.001). Adjusted-dose warfarin reduced cardioembolic strokes by 83% (p < 0.001) relative to aspirin in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: